Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
The cost effectiveness of treatments that have changed the “natural history” of a chronic progressive disease needs to be evaluated over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA) and should be started as early as possible. A...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | International Journal of Rheumatology |
Online Access: | http://dx.doi.org/10.1155/2011/845496 |
id |
doaj-9cf7eb12f6e843de81e8325d95374280 |
---|---|
record_format |
Article |
spelling |
doaj-9cf7eb12f6e843de81e8325d953742802020-11-25T00:34:42ZengHindawi LimitedInternational Journal of Rheumatology1687-92601687-92792011-01-01201110.1155/2011/845496845496Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review LiteratureMaurizio Benucci0Gianantonio Saviola1Mariangela Manfredi2Piercarlo Sarzi-Puttini3Fabiola Atzeni4Rheumatology Unit Department of Internal Medicine, Hospital S. Giovanni di Dio, Azienda Sanitaria di Firenze, 50143 Florence, ItalyRheumatology and Rehabilitation Unit, Salvatore Maugeri Foundation IRCCS, 46042 Mantua, ItalyImmunology and Allergology Laboratory Unit, Hospital S. Giovanni di Dio, Azienda Sanitaria di Firenze, 50143 Florence, ItalyRheumatology Unit, Sacco University Hospital, 20127 Milan, ItalyRheumatology Unit, Sacco University Hospital, 20127 Milan, ItalyThe cost effectiveness of treatments that have changed the “natural history” of a chronic progressive disease needs to be evaluated over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA) and should be started as early as possible. A number of studies have shown that they are effective in improving disease activity and function, and in joint damage. Our review was focused on revision and critical evaluation of the studies including the literature on cost effectiveness of DMARDs (cyclosporine A, sulphasalazine, leflunomide, and methotrexate). The European League Against Rheumatism (EULAR) recommendations showed that traditional DMARDs are cost effective at the time of disease onset. They are less expensive than biological DMARDs and can be useful in controlling disease activity in early RA.http://dx.doi.org/10.1155/2011/845496 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maurizio Benucci Gianantonio Saviola Mariangela Manfredi Piercarlo Sarzi-Puttini Fabiola Atzeni |
spellingShingle |
Maurizio Benucci Gianantonio Saviola Mariangela Manfredi Piercarlo Sarzi-Puttini Fabiola Atzeni Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature International Journal of Rheumatology |
author_facet |
Maurizio Benucci Gianantonio Saviola Mariangela Manfredi Piercarlo Sarzi-Puttini Fabiola Atzeni |
author_sort |
Maurizio Benucci |
title |
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature |
title_short |
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature |
title_full |
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature |
title_fullStr |
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature |
title_full_unstemmed |
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature |
title_sort |
cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. a systematic review literature |
publisher |
Hindawi Limited |
series |
International Journal of Rheumatology |
issn |
1687-9260 1687-9279 |
publishDate |
2011-01-01 |
description |
The cost effectiveness of treatments that have changed the “natural history” of a chronic progressive disease needs to be evaluated over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA) and should be started as early as possible. A number of studies have shown that they are effective in improving disease activity and function, and in joint damage. Our review was focused on revision and critical evaluation of the studies including the literature on cost effectiveness of DMARDs (cyclosporine A, sulphasalazine, leflunomide, and methotrexate). The European League Against Rheumatism (EULAR) recommendations showed that traditional DMARDs are cost effective at the time of disease onset. They are less expensive than biological DMARDs and can be useful in controlling disease activity in early RA. |
url |
http://dx.doi.org/10.1155/2011/845496 |
work_keys_str_mv |
AT mauriziobenucci costeffectivenessanalysisofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisasystematicreviewliterature AT gianantoniosaviola costeffectivenessanalysisofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisasystematicreviewliterature AT mariangelamanfredi costeffectivenessanalysisofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisasystematicreviewliterature AT piercarlosarziputtini costeffectivenessanalysisofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisasystematicreviewliterature AT fabiolaatzeni costeffectivenessanalysisofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisasystematicreviewliterature |
_version_ |
1725311952570286080 |